Results 71 to 80 of about 6,034 (173)

Blocking CCR5 activity by maraviroc augmentation in post-stroke depression: a proof-of-concept clinical trial

BMC Neurology
Background Post-stroke depression (PSD) is a significant impediment to successful rehabilitation and recovery after a stroke. Current therapeutic options are limited, leaving an unmet demand for specific and effective therapeutic options.
Oren Tene, Jeremy Molad, Ofer Rotschild, Aviva Alpernas, Muhamad Hawwari, Estelle Seyman, Nir Giladi, Hen Hallevi, Einor Ben Assayag   +8 more
doaj   +1 more source

Maraviroc [PDF]

, 2020
openaire   +1 more source

Blockade of CCR5+ T Cell Accumulation in the Tumor Microenvironment Optimizes Anti‐TGF‐β/PD‐L1 Bispecific Antibody

Advanced Science
In the previous studies, anti‐TGF‐β/PD‐L1 bispecific antibody YM101 is demonstrated, with superior efficacy to anti‐PD‐L1 monotherapy in multiple tumor models.
Ming Yi, Tianye Li, Mengke Niu, Yuze Wu, Bin Zhao, Zhuoyang Shen, Shengtao Hu, Chaomei Zhang, Xiaojun Zhang, Jing Zhang, Yongxiang Yan, Pengfei Zhou, Qian Chu, Zhijun Dai, Kongming Wu   +14 more
doaj   +1 more source

Clinical use of CCR5 inhibitors in HIV and beyond

Journal of Translational Medicine, 2010
Since the discovery of CCR5 as a coreceptor for HIV entry, there has been interest in blockade of the receptor for treatment and prevention of HIV infection.
Gilliam Bruce, Riedel David, Redfield Robert   +2 more
doaj  

Maraviroc for Stroke Recovery (MASTER): protocol for a phase 2 double-blind placebo-controlled randomised clinical trial. [PDF]

BMJ Open
Broc N, Byczynski G, Dirren E, Carrera E.   +3 more
europepmc   +1 more source

Donor macrophage depletion permits posttransplant tolerance induction in a murine islet transplant model. [PDF]

Am J Transplant
Dilts M, Fay OK, Yu Y, Jordan CZ, Luo X.
europepmc   +1 more source

Tumor-educated macrophages promote cytokine-driven lung colonization in triple-negative breast cancer. [PDF]

Oncoimmunology
Rosado-Sanz M, Martínez-Alarcón N, Meel MH, Rius-Perez S, Tolboom ZJ, Salvador-Coloma C, Burgos-Panadero R, Coronado E, Montoliu G, Casals E, Esteve-Codina A, Ripoll F, Santaballa A, Font de Mora J.   +13 more
europepmc   +1 more source

Harnessing lipid-driven immunometabolic pathways in omental metastases to enhance immunotherapy in patients with ovarian cancer. [PDF]

Signal Transduct Target Ther
Suarez-Carmona M, Hampel M, Zhang XW, Pöchmann A, Grauling-Halama SA, Valous NA, Charoentong P, Ferber D, Wissfeld J, Höflich A, Goriely S, Detavernier A, Azouz A, Rongvaux A, Zukunft S, Fleming I, Okun JG, Baracos V, Heikenwalder M, Zitvogel L, Xu X, Xu C, Volkmar M, Schraivogel D, Steinmetz L, Hamanishi J, Mandai M, Gaida M, Mokry T, Nattenmüller J, Sedlaczek O, Monje N, Schwab R, Hasenburg A, Mavratzas A, Boger RJ, Marmé F, Schott S, Halama N.   +38 more
europepmc   +1 more source

Physiologically Based Pharmacokinetic Modeling to Assess Antiretroviral-BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Regimens. [PDF]

Pharmaceutics
Chen L, Wang X, Li L, Yang Y, Liu Y, Chen W.   +5 more
europepmc   +1 more source

Chemokine-defined macrophage niches establish spatial organization of tumor immunity. [PDF]

Nat Immunol
Ghosh S, Li X, Rawat K, Dighal A, Kalinowski S, Hosseini R, Kolling FW, Ringelberg CS, Jakubzick CV.   +8 more
europepmc   +1 more source